STOCK TITAN

ZyVersa Therapeutics Inc - ZVSA STOCK NEWS

Welcome to our dedicated news page for ZyVersa Therapeutics (Ticker: ZVSA), a resource for investors and traders seeking the latest updates and insights on ZyVersa Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZyVersa Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZyVersa Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-69.07%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
management
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
ZyVersa Therapeutics Inc

Nasdaq:ZVSA

ZVSA Rankings

ZVSA Stock Data

5.39M
7.50M
0.83%
2.65%
7.64%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Weston

About ZVSA

variant pharmaceuticals is an orphan drug company leveraging advanced proprietary technologies to develop best-in-class drugs for patients with rare diseases. our accomplished leadership team, each with more than 15 years of demonstrated success in the biopharmaceutical and medical industries, focuses on assuring that our development efforts serve the needs of all our stakeholders: patients, health care providers, payors, and our investors. our evolving product pipeline is targeted to the $100+ billion orphan drug market. our lead orphan drug candidate is hydroxypropyl beta cyclodextrin (hpβcd) for chronic treatment of two orphan indications, var 200: focal segmental glomerulosclerosis (fsgs) and var 300: alport syndrome (as). both of these conditions are rare progressive forms of kidney disease associated with accumulation of cholesterol and lipids, contributing to impaired kidney function, ultimately leading to dialysis and/or kidney transplantation. hpβcd entraps and removes lipids